KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Receivables (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Receivables for 17 consecutive years, with $908.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 37.5% year-over-year to $908.2 million, compared with a TTM value of $908.2 million through Dec 2025, up 37.5%, and an annual FY2025 reading of $908.2 million, up 37.5% over the prior year.
  • Receivables was $908.2 million for Q4 2025 at Biomarin Pharmaceutical, up from $790.3 million in the prior quarter.
  • Across five years, Receivables topped out at $908.2 million in Q4 2025 and bottomed at $373.4 million in Q4 2021.
  • Average Receivables over 5 years is $591.0 million, with a median of $604.1 million recorded in 2023.
  • The sharpest move saw Receivables decreased 16.72% in 2021, then surged 39.0% in 2023.
  • Year by year, Receivables stood at $373.4 million in 2021, then rose by 23.55% to $461.3 million in 2022, then soared by 37.37% to $633.7 million in 2023, then grew by 4.23% to $660.5 million in 2024, then skyrocketed by 37.5% to $908.2 million in 2025.
  • Business Quant data shows Receivables for BMRN at $908.2 million in Q4 2025, $790.3 million in Q3 2025, and $855.9 million in Q2 2025.